GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Short Interest

Wuhan YZY Biopharma Co (HKSE:02496) Short Interest


View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Wuhan YZY Biopharma Co's Short Interest

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan YZY Biopharma Co's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Short Interest distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's Short Interest falls into.


;
;

Wuhan YZY Biopharma Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Short Interest
Comparable Companies
HKSE:06998 HKSE:06622 HKSE:01875 HKSE:03681 HKSE:01244 HKSE:02511 HKSE:02563 HKSE:02126 HKSE:02566 HKSE:06628 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN
Website
https://en.yzybio.com
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing a new class of medicines in respect to anti-tumor bispecific antibody. It generates the majority of its revenue from PRC.
Executives
Wen Zhicheng 2201 Interest of corporation controlled by you
Guo Hong Wei
Dragon Merit Holdings Limited 2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si 2101 Beneficial owner
Cspc Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
Robust Sun Holdings Limited 2201 Interest of corporation controlled by you
Wang Hongjie 2201 Interest of corporation controlled by you
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si 2201 Interest of corporation controlled by you
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Cdh 2018 Vgc Investment Fund, L.p. 2201 Interest of corporation controlled by you
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng

Wuhan YZY Biopharma Co Headlines

No Headlines